In the PLSD, there is a relative incidence of breast cancer of 1·3 for path_MLH1, 1·2 for path_MSH2 and 1·4 for path_MSH6 carriers. In this cohort, the confidence intervals all include 1 and it is not possible to confirm a significant increase in breast cancer risk at this time. Here, MLH1 is linked to breast cancer.